IDRX-42 Phase 1b clinical trial in UK

Some GISTS develop resistance to standard drug treatment (e.g. imatinib, sunitinib, regorafenib, ripritinib).  A new drug is being trialed to prevent the emergence of sub-clones or to treat TKI resistant GISTs.  This trial is being coordinated by Professor Robin Jones at the Royal Marsden Hospital in London.

Posted in GIST News.